Climb Bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Products    Trials    News 
  • ||||||||||  Rituxan (rituximab) / Roche
    A Phase 1b/ 2a study of budoprutug in patients with immune thrombocytopenia (ITP) (OCCC - West Halls B3-B4) -  Nov 4, 2025 - Abstract #ASH2025ASH_2756;    
    P1/2
    Second-line options include either a recombinant humanthrombopoietin receptor agonist (TPO-RA) or B-cell depletion using an anti-CD20 monoclonal antibody(mAb; rituximab)... This Phase 1b/2a study will provide initial evidence regarding the safety and efficacy ofCD19-targeted B-cell depletion with multiple doses of budoprutug in patients with ITP.
  • ||||||||||  budoprutug (TNT119) / Climb Bio
    Enrollment open:  PrisMN: A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy (clinicaltrials.gov) -  Sep 10, 2025   
    P2,  N=45, Recruiting, 
    This Phase 1b/2a study will provide initial evidence regarding the safety and efficacy ofCD19-targeted B-cell depletion with multiple doses of budoprutug in patients with ITP. Not yet recruiting --> Recruiting
  • ||||||||||  budoprutug (TNT119) / Eliem Therap
    Enrollment change, Trial withdrawal:  Phase 1b/2a in SLE With Budoputug (clinicaltrials.gov) -  Oct 16, 2024   
    P1/2,  N=0, Withdrawn, 
    Not yet recruiting --> Recruiting N=40 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  budoprutug (TNT119) / Eliem Therap
    New P1/2 trial:  Phase 1b/2a in SLE With Budoputug (clinicaltrials.gov) -  Aug 26, 2024   
    P1/2,  N=40, Not yet recruiting, 
  • ||||||||||  budoprutug (TNT119) / Eliem Therap
    Enrollment closed, Phase classification, Enrollment change, Trial completion date:  Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy (clinicaltrials.gov) -  Feb 15, 2024   
    P1/2,  N=6, Active, not recruiting, 
    Trial completion date: Aug 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Sponsor change Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | N=30 --> 6 | Trial completion date: Oct 2023 --> Aug 2024
  • ||||||||||  budoprutug (TNT119) / Eliem Therap
    Enrollment closed, Trial completion date, Trial primary completion date:  Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS) (clinicaltrials.gov) -  Jan 13, 2023   
    P2,  N=20, Active, not recruiting, 
    To date, limited clinical data are available for these investigational treatments and further studies are required to assess their potential value in addressing unmet needs in epilepsy management. Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Nov 2023 --> Jun 2023
  • ||||||||||  ETX-810 / Eliem Therap
    Trial completion:  Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain (clinicaltrials.gov) -  Jun 30, 2022   
    P2,  N=148, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Feb 2024 --> Nov 2023 | Trial primary completion date: Nov 2023 --> Jun 2023 Recruiting --> Completed
  • ||||||||||  KRM-81 / RespireRx, Ztalmy (ganaxolone oral) / Marinus
    Review, Journal:  The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders. (Pubmed Central) -  Mar 9, 2022   
    These GABAkines and non-steroid compounds (GRX-917, a TSPO binding site ligand), darigabat (CVL-865), an α2/3/5-preferring GABAkine, SAN711, an α3-preferring GABAkine, and the α2/3-preferring GABAkine, KRM-II-81, bring new therapeutic promise to this highly utilized medicinal target in neurology and psychiatry...KRM-II-81 also produces anxiolytic- and antidepressant-like effects in rodent models. Other key features of the pharmacology of this compound are its low sedation rate, lack of tolerance development, and the ability to prevent the development of seizure sensitization.
  • ||||||||||  ETX-810 / Eliem Therap
    Trial completion date, Trial primary completion date:  Efficacy and Safety of ETX-018810 in Subjects With Lumbosacral Radicular Pain (clinicaltrials.gov) -  Jan 19, 2022   
    P2,  N=122, Recruiting, 
    Other key features of the pharmacology of this compound are its low sedation rate, lack of tolerance development, and the ability to prevent the development of seizure sensitization. Trial completion date: Oct 2021 --> Jul 2022 | Trial primary completion date: Oct 2021 --> Jul 2022